UNASSIGNED: Authors reviewed literature published through July 2023 on platforms such as PubMed, clinicaltrials.gov, and manufacturer/FDA drug labels, focusing on the development of TRKi, native functions of TRK, phenotype of congenital TRK aberrancies, efficacy, and safety profile of TRKi in clinical trials and investigator reports, and on/off target adverse effects associated with TRKi (Appendix A).
UNASSIGNED: TRKi have histology-agnostic activity against tumors with NTRK gene fusions. TRKi are generally well tolerated with a side effect profile that compares favorably to cytotoxic chemotherapy. There are numerous ongoing studies investigating TRKi as frontline, adjuvant, and salvage therapy. It will be critical to continue to gather long-term safety data on the use of these agents, particularly in children.
■作者回顾了截至2023年7月在PubMed等平台上发表的文献,clinicaltrials.gov,和制造商/FDA药物标签,专注于TRKi的发展,TRK的本机函数,先天性TRK异常的表型,TRKi在临床试验和研究者报告中的疗效和安全性,以及与TRKi相关的开/关目标不良反应。
■TRKi对NTRK基因融合的肿瘤具有组织学不可知的活性。TRKi通常具有良好的耐受性,具有与细胞毒性化疗相比有利的副作用特征。有许多正在进行的研究以TRKi为前线,佐剂,和抢救疗法。继续收集有关这些药物使用的长期安全数据至关重要。特别是在儿童中。